If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Jenny Lee is a medical oncologist who is part of the Precision Cancer Therapy Laboratory as the clinical lead. Her research interests include melanoma and lung cancer, especially in understanding the mechanisms behind immunotherapy response and resistance, and biomarker discovery.

Fingerprint Dive into the research topics where Jenny Lee is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
DNA Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Antibodies Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2017

Research Outputs 2014 2019

  • 408 Citations
  • 6 h-Index
  • 10 Article
  • 4 Meeting abstract
  • 2 Review article

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Immunotherapy
Melanoma
Cytokines
Confidence Intervals
Therapeutics

Monitoring melanoma using circulating free DNA

Diefenbach, R. J., Lee, J. H. & Rizos, H., 13 Feb 2019, In : American Journal of Clinical Dermatology. 20, 1, p. 1-12 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Melanoma
Nucleic Acids
DNA
Polymerase Chain Reaction
Mutation

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., Guminski, A., Lee, J. H., Lee, H., Ferguson, P. M., Rawson, R. V., Wilmott, J. S., Thompson, J. F., Kefford, R. F., Ch'ng, S., Stretch, J. R., Emmett, L., Kapoor, R., Rizos, H., Spillane, A. J. & 2 othersScolyer, R. A. & Menzies, A. M., 1 Jul 2019, In : The Lancet Oncology. 20, 7, p. 961-971 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Melanoma
Mutation
dabrafenib
trametinib
Neoadjuvant Therapy

Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies

Lee, J. H., Long, G. V., Menzies, A. M., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R. F., Rizos, H. & Carlino, M. S., 1 May 2018, In : JAMA Oncology. 4, 5, p. 717-721 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Melanoma
Cell Death
Antibodies
DNA
Neoplasms

Evaluation of commercial kits for purification of circulating free DNA

Diefenbach, R. J., Lee, J. H., Kefford, R. F. & Rizos, H., 21 Sep 2018, In : Cancer Genetics. 228-229, p. 21-27 7 p.

Research output: Contribution to journalArticleResearchpeer-review

DNA
Nucleic Acids
Workflow
Plasma Cells
Serum

Prizes

Sydney Vital travel scholarship

Jenny Lee (Recipient), 26 Jul 2018

Prize

Oncology